Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.78 Consensus Target Price from Analysts

Key Points

• Viridian Therapeutics has received an average recommendation of "Moderate Buy" from ten analysts, with one holding and nine buy ratings.
• The average one-year price target for the stock is approximately $37.78, reflecting optimism among analysts regarding its future performance.
• Viridian's latest earnings report indicated an EPS of ($1.00), meeting analyst estimates, with revenue exceeding expectations at $0.08 million.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $37.7778.

A number of equities analysts have recently weighed in on VRDN shares. Needham & Company LLC dropped their target price on Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Oppenheimer upped their target price on Viridian Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. The Goldman Sachs Group upped their target price on Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Jefferies Financial Group assumed coverage on Viridian Therapeutics in a research note on Monday, August 25th. They issued a "buy" rating and a $44.00 price target for the company. Finally, Royal Bank Of Canada lowered their price target on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th.

Institutional Investors Weigh In On Viridian Therapeutics

A number of large investors have recently added to or reduced their stakes in VRDN. Ameriprise Financial Inc. boosted its position in Viridian Therapeutics by 16.2% during the fourth quarter. Ameriprise Financial Inc. now owns 48,793 shares of the company's stock worth $935,000 after purchasing an additional 6,806 shares during the period. Bank of America Corp DE lifted its holdings in shares of Viridian Therapeutics by 36.5% during the fourth quarter. Bank of America Corp DE now owns 247,107 shares of the company's stock worth $4,737,000 after buying an additional 66,138 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Viridian Therapeutics by 40.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,400 shares of the company's stock worth $930,000 after buying an additional 13,990 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Viridian Therapeutics by 198.2% during the fourth quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company's stock worth $13,055,000 after buying an additional 452,627 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Viridian Therapeutics by 74.1% during the fourth quarter. ProShare Advisors LLC now owns 20,584 shares of the company's stock worth $395,000 after buying an additional 8,761 shares during the last quarter.

Viridian Therapeutics Price Performance

NASDAQ VRDN remained flat at $19.55 on Friday. The company's stock had a trading volume of 119,112 shares, compared to its average volume of 884,416. The company's fifty day moving average price is $18.11 and its 200 day moving average price is $15.50. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -5.11 and a beta of 0.53. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.00). The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.81) EPS. As a group, equities analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.